A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
Monk B.J., Brady M.F., Aghajanian C., Lankes H.A., Rizack T., Leach J., Fowler J.M., Higgins R., Hanjani P., Morgan M. et al., 2017/05/01. Annals of oncology, 28 (5) pp. 996-1004. Peer-reviewed.
ici le détail